Search results for "dysfunction"

showing 10 items of 1129 documents

Arterial stiffness in symptomatic smokers with normal lung function

2017

Chronic obstructive pulmonary disease (COPD) is associated with cardiovascular morbidity and mortality. Arterial stiffness and endothelial dysfunction index are validated surrogate cardiovascular markers and are increased in subjects with COPD. We tested whether increased arterial stiffness and endothelial dysfunction occur in symptomatic smokers with no evidence of bronchial obstruction. Clinical and lung functional assessments were conducted in smoker subjects with chronic respiratory symptoms and in COPD patients. Pulse wave velocity (PWV), aortic augmentation index (AIx) and reactive hyperaemia index (RHI) were measured to estimate the cardiovascular risk. 48 smokers (male n=37, female …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPathology1lcsh:Medicine030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesHyperaemia0302 clinical medicineInternal medicinemedicineEndothelial dysfunctionRespiratory systemPulse wave velocityCOPDLungbusiness.industrylcsh:ROriginal ArticlesAortic Augmentation Indexmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structure030228 respiratory systemCardiologyArterial stiffnessmedicine.symptombusiness
researchProduct

Systemic Thrombolytic Therapy for Acute Pulmonary Embolism: Who Is a Candidate?

2017

Pulmonary embolism (PE) is a major cause of both acute and long-term morbidity for a large number of patients worldwide, and massive PE is frequently fatal. Right ventricular (RV) dysfunction is a key determinant of prognosis in the acute phase of PE. Patients with clinically overt RV failure, that is, with cardiogenic shock or persistent hypotension at presentation (acute high-risk PE), are clearly in need of immediate reperfusion treatment with systemic thrombolysis or, alternatively, surgical or catheter-directed techniques. On the other hand, within the large group of patients presenting without hemodynamic instability, the bleeding risk of full-dose intravenous thrombolytic treatment h…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyVentricular Dysfunction Rightmedicine.medical_treatmentHemodynamicsSalvage therapy030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicineFibrinolysismedicineHumansThrombolytic TherapyDecompensation030212 general & internal medicineWatchful WaitingIntensive care medicineSalvage Therapybusiness.industryCardiogenic shockAnticoagulantsThrombolysisPrognosismedicine.diseasePulmonary embolismAcute DiseaseCardiologyPulmonary EmbolismbusinessWatchful waitingSeminars in Respiratory and Critical Care Medicine
researchProduct

Novel therapeutical approaches to managing atherosclerotic risk

2021

Atherosclerosis is a multifactorial vascular disease that leads to inflammation and stiffening of the arteries and decreases their elasticity due to the accumulation of calcium, small dense Low Density Lipoproteins (sdLDL), inflammatory cells, and fibrotic material. A review of studies pertaining to cardiometabolic risk factors, lipids alterations, hypolipidemic agents, nutraceuticals, hypoglycaemic drugs, atherosclerosis, endothelial dysfunction, and inflammation was performed. There are several therapeutic strategies including Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors, inclisiran, bempedoic acid, Glucagon-Like Peptide-1 Receptor agonists (GLP-1 RAs), and nutraceuticals t…

QH301-705.5InflammationReview030204 cardiovascular system & hematologyPharmacologyCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineLipid oxidationmedicineAnimalsHumans030212 general & internal medicineMolecular Targeted TherapyPhysical and Theoretical ChemistryEndothelial dysfunctionBiology (General)Molecular BiologyQD1-999SpectroscopyInnovative therapiesMolecular signalingVascular diseasebusiness.industryPCSK9Organic ChemistryGeneral MedicineProprotein convertasemedicine.diseaseAtherosclerosisComputer Science ApplicationsManagementChemistryInflammationsAtheromaOxidative stressHypolipidemic Agentslipids (amino acids peptides and proteins)Nutraceuticalsmedicine.symptombusiness
researchProduct

Individualized counselling for active aging: protocol of a single-blinded, randomized controlled trial among older people (the AGNES intervention stu…

2019

Background: Active aging has been established as a policy goal for aging societies. We define active aging at the individual level as striving for elements of well-being through activities in relation to a person’s goals, functional capacities and opportunities. Increasing evidence suggests that any meaningful activity is beneficial for different aspects of well-being in older people. The aim of the present randomized controlled trial is to test the feasibility and effectiveness of a one-year community-based intervention on active aging. The AGNES intervention aims at increasing older peoples’ participation in self-selected valued activities. Methods: The proposed study is a two-arm single-…

Quality of lifeCounselingMalebehavior changeAgingIndividualized counsellingtheory-based interventionHealth Behavioryksilöllinen hoitophysical activityelämänlaatulcsh:GeriatricsStudy ProtocolBehavior changeTheory-based interventionHumansCognitive DysfunctionSingle-Blind MethodExerciseFinlandAutonomy supportAgedosallistuminenMobilityAged 80 and overPhysical activityDepressionagingautonomiaParticipationlcsh:RC952-954.6autonomy supportikääntyminenliikkuvuusFemaleindividualized counsellingyksilöllisyysfyysinen aktiivisuusBMC Geriatrics
researchProduct

Mindfulness, rumination, and coping skills in young women with Eating Disorders: A comparative study with healthy controls

2019

Eating Disorders (ED) have been associated with dysfunctional coping strategies, such as rumination. Promoting alternative ways of experiencing mental events, based on a mindfulness approach, might be the clue for learning more effective coping and regulatory strategies among young women with ED. This study examined the comparison between patients with ED diagnosis and healthy subjects in mindfulness, rumination and effective coping. In addition, we analyzed the independent association of those with the presence of ED. The study sample was formed by two groups of young women ranged 13-21 years: Twenty-five with an ED diagnosis and 25 healthy subjects. They were assessed by using the Freibur…

Questionnaires050103 clinical psychologyCoping (psychology)MindfulnessEating DisordersEmotionsSocial Sciences0302 clinical medicineCognitionSurveys and QuestionnairesAdaptation PsychologicalMedicine and Health SciencesPsychologyMultidisciplinary05 social sciencesQHealthy subjectsRCognitionEating disordersMeditacióHealth Education and AwarenessResearch DesignMedicineFemalemedicine.symptomPsychologyMindfulnessClinical psychologyResearch ArticleAdolescentScienceMetacognitionDysfunctional familyModels PsychologicalResearch and Analysis MethodsFeeding and Eating Disorders03 medical and health sciencesYoung AdultMental Health and PsychiatrymedicineHumans0501 psychology and cognitive sciencesTrastorns de la conducta alimentàriaBehaviorSurvey ResearchBehavioral DisordersBiology and Life Sciencesmedicine.disease030227 psychiatryHealth CareRumination CognitivePsicologiaSpainCase-Control StudiesRuminationCognitive ScienceMetacognitionNeuroscience
researchProduct

Inhibition of Rac1 GTPase Decreases Vascular Oxidative Stress, Improves Endothelial Function, and Attenuates Atherosclerosis Development in Mice

2021

Aims: Oxidative stress and inflammation contribute to atherogenesis. Rac1 GTPase regulates pro-oxidant NADPH oxidase activity, reactive oxygen species (ROS) formation, actin cytoskeleton organization and monocyte adhesion. We investigated the vascular effects of pharmacological inhibition of Rac1 GTPase in mice.Methods and Results: We treated wild-type and apolipoprotein E-deficient (ApoE−/−) mice with Clostridium sordellii lethal toxin (LT), a Rac1 inhibitor, and assessed vascular oxidative stress, expression and activity of involved proteins, endothelial function, macrophage infiltration, and atherosclerosis development. LT-treated wild-type mice displayed decreased vascular NADPH oxidase…

RHOAInflammationVascular permeabilityfree radicalsPharmacologyCardiovascular Medicinemedicine.disease_causeActin cytoskeleton organizationendothelial functionmedicineoxidative stressDiseases of the circulatory (Cardiovascular) systemddc:610Endothelial dysfunctionOriginal Researchchemistry.chemical_classificationReactive oxygen speciesNADPH oxidaseGTPasesbiologymedicine.diseasechemistryatherosclerosis endothelial function oxidative stress free radicals Rac1 GTPasesRC666-701biology.proteinmedicine.symptomatherosclerosisCardiology and Cardiovascular MedicineOxidative stressRac1Frontiers in Cardiovascular Medicine
researchProduct

Peripheral artery disease: potential role of ACE-inhibitor therapy

2008

Giuseppe Coppola, Giuseppe Romano, Egle Corrado, Rosa Maria Grisanti, Salvatore NovoDepartment of Internal Medicine, Cardiovascular and Nephro-Urological Diseases, Chair of Cardiovascular Disease, University of Palermo, Palermo, ItalyAbstract: Subjects with peripheral arterial disease (PAD) of the lower limbs are at high risk for cardiovascular and cerebrovascular events and the prevalence of coronary artery disease in such patients is elevated. Recent studies have shown that regular use of cardiovascular medications, such as therapeutic and preventive agents for PAD patients, seems to be promising in reducing long-term mortality and morbidity. The angiotensin-converting-enzyme (ACE) system…

Ramiprillcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyPathologyACE inhibitorsEndocrinology Diabetes and MetabolismBradykininAngiotensin-Converting Enzyme InhibitorsReviewDiseaseendothelial dysfunctionCoronary artery diseasechemistry.chemical_compoundperipheral arterial diseaseInternal medicineHumansMedicinePharmacology (medical)Endothelial dysfunctionCell ProliferationSubclinical infectionPeripheral Vascular Diseasesbusiness.industryFibrinolysisPublic Health Environmental and Occupational HealthCardiovascular AgentsPeripheral artery disease ACE-inhibitorintermittent claudicationHematologyGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolareperipheral arterial disease.Oxidative StressTreatment OutcomeLower ExtremitychemistryCardiovascular Diseaseslcsh:RC666-701ACE-inhibitorsACE inhibitorCardiovascular agentCardiologyEndothelium VascularatherosclerosisCardiology and Cardiovascular Medicinebusinessmedicine.drugVascular Health and Risk Management
researchProduct

Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMI…

2013

Claudio Borghi,1 Ettore Ambrosioni,1 Stefano Omboni,2 Arrigo FG Cicero,1 Stefano Bacchelli,1 Daniela Degli Esposti,1 Salvatore Novo,3 Dragos Vinereanu,4 Giuseppe Ambrosio,5 Giorgio Reggiardo,6 Dario Zava7 1Unit of Internal Medicine, Policlinico S Orsola, University of Bologna, Bologna, Italy; 2Italian Institute of Telemedicine, Varese, Italy; 3Division of Cardiology, University of Palermo, Palermo, Italy; 4University and Emergency Hospital, Bucharest, Romania; 5Division of Cardiology, University of Perugia, Perugia, Italy; 6Mediservice, Milano, Italy; 7Istituto Lusofarmaco d'Italia SpA, Peschiera Borromeo, Italy Background: In SMILE-4 (the Survival of Myocardial Infarction Long-term…

Ramiprilmedicine.medical_specialtyCost effectivenessEconomics Econometrics and Finance (miscellaneous)Populationacute myocardial infarctionramiprilchemistry.chemical_compoundInternal medicinePost-hoc analysismedicinezofenoprilMyocardial infarctioneducationcost-effectivenesshealth care economics and organizationsOriginal Researchleft ventricular dysfunctioneducation.field_of_studylcsh:R5-920business.industryHealth Policylcsh:RM1-950acetylsalicylic acidmedicine.diseaseSMILE studycost effectiveness analysis (CEA)Confidence intervalZofenoprilangiotensin-converting enzyme inhibitorsClinicoEconomics and Outcomes Researchlcsh:Therapeutics. PharmacologychemistryCardiologyNumber needed to treatMedical emergencybusinesslcsh:Medicine (General)medicine.drug
researchProduct

Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfu…

2015

Objective Conflicting evidence exists on the benefits of treating patients with coronary artery disease and preserved left ventricular ejection fraction (LVEF) with an ACE inhibitor. This retrospective analysis of the SMILE-4 Study sought to compare the efficacy of zofenopril 60 mg plus acetylsalicylic acid (ASA) versus ramipril 10 mg plus ASA 100 mg in patients with acute myocardial infarction (AMI) and heart failure, according to an impaired or preserved LVEF. Methods The primary study end point was 1-year combined occurrence of death or hospitalisation for cardiovascular causes. A preserved LVEF was defined by a baseline LVEF >40% and an impaired one by an LVEF ≤40%. Results 448 patients…

Ramiprilmedicine.medical_specialtyacute myocardial infarctionInfarctionramiprilCoronary Artery DiseaseCoronary artery diseasechemistry.chemical_compoundInternal medicinemedicinezofenopril1506cardiovascular diseasesMyocardial infarctionleft ventricular dysfunctionEjection fractionbusiness.industryleft ventricular ejection fractionmedicine.diseaseZofenoprilangiotensin-converting enzyme inhibitorsangiotensin-converting enzyme inhibitorchemistryacute myocardial infarction; angiotensin-converting enzyme inhibitors; left ventricular dysfunction; left ventricular ejection fractionHeart failureACE inhibitorcardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologyBiomedical engineeringmedicine.drugOpen Heart
researchProduct

Diuretic vs. placebo in intermediate-risk acute pulmonary embolism: a randomized clinical trial

2022

Abstract Aims The role of diuretics in patients with intermediate-risk pulmonary embolism (PE) is controversial. In this multicentre, double-blind trial, we randomly assigned normotensive patients with intermediate-risk PE to receive either a single 80 mg bolus of furosemide or a placebo. Methods and results Eligible patients had at least a simplified PE Severity Index (sPESI) ≥1 with right ventricular dysfunction. The primary efficacy endpoint assessed 24 h after randomization included (i) absence of oligo-anuria and (ii) normalization of all sPESI items. Safety outcomes were worsening renal function and major adverse outcomes at 48 hours defined by death, cardiac arrest, mechanical ventil…

Randomizationmedicine.medical_treatmentVentricular Dysfunction Right[SDV]Life Sciences [q-bio]Critical Care and Intensive Care MedicinePlacebolaw.inventionRandomized controlled trialDouble-Blind MethodlawFurosemidemedicineHumansDiureticsbusiness.industryFurosemideGeneral Medicinemedicine.diseasePulmonary embolismBlood pressureTreatment OutcomeAnesthesiaAcute DiseaseDiureticBolus (digestion)Cardiology and Cardiovascular MedicinebusinessPulmonary Embolismmedicine.drug
researchProduct